Key result
Postoperative intravenous amiodarone followed by oral amiodarone significantly reduced the incidence of new-onset atrial fibrillation compared to placebo (11.8% vs 26.5%) after off-pump coronary artery bypass grafting.
Why the study?
Does postoperative amiodarone prophylaxis reduce the incidence of atrial fibrillation in patients undergoing off-pump coronary artery bypass surgery?
RCT (n=144)
Placebo-controlled
Randomized
Does postoperative amiodarone prophylaxis reduce the incidence of atrial fibrillation in patients undergoing off-pump coronary artery bypass surgery?
Absolute Event Rate: 11.8% vs 26.5%
p-value: p=0.025
Postoperative intravenous amiodarone followed by oral amiodarone significantly reduces the incidence of atrial fibrillation and the maximum ventricular rate in patients undergoing off-pump coronary artery bypass grafting.
Postoperative amiodarone reduces new-onset AF after off-pump CABG; confirms prophylaxis benefit in this randomized cohort.
BACKGROUND: Atrial fibrillation is still a frequent complication that increases morbidity after coronary artery bypass grafting. This prospective randomized study is designed to define efficacy of postoperative amiodarone prophylaxis in preventing atrial fibrillation after off-pump coronary artery bypass grafting. METHODS: One hundred forty-four patients who underwent elective off-pump coronary artery bypass grafting were enrolled for the study. Seventy-six patients (amiodarone group) received 5 mg/kg loading amiodarone infusion in the first postoperative hour, followed by 10 mg/kg for the first 24 hours. After 24 hours, patients received 600 mg/day amiodarone orally for 7 days and 200 mg/day until the end of the postoperative first month. Sixty-eight patients received placebo (control group). RESULTS: Preoperative characteristics and operative variables of the patients were similar in both groups. Incidence of new-onset atrial fibrillation and maximal ventricular rate response were recorded. The incidence of new-onset atrial fibrillation (11.8% versus 26.5%) (P = .025) and maximal ventricular rate response (109 +/- 13.8 beats/min versus 124.5 +/- 13.9 beats/min) (P = .011) were significantly lower in the amiodarone group. Duration of atrial fibrillation was 17.5 +/- 8.1 hours for the amiodarone group compared with 32.7 +/- 12 hours for the control group (P = .002). CONCLUSION: Postoperative intravenous amiodarone prophylaxis followed by oral amiodarone significantly reduces the incidence of atrial fibrillation after off-pump coronary artery bypass grafting and the ventricular rate during atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Türk et al. (2007) conducted an RCT in Patients undergoing elective off-pump coronary artery bypass grafting (OPCAB) (n=144). Amiodarone vs. Placebo (5% glucose IV for 24 hours, then standard medication) was evaluated on Incidence of new-onset atrial fibrillation (p=0.025). Postoperative intravenous amiodarone followed by oral amiodarone significantly reduced the incidence of new-onset atrial fibrillation compared to placebo (11.8% vs 26.5%) after off-pump coronary artery bypass grafting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: